Oral Carnosine for Neuromuscular Performance in Multiple Sclerosis
Oral Carnosine for Neuromuscular Performance, Brain Biomarkers of Carnosine Metabolism and Health-related Quality of Life in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
This trial finished 7 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Carnosine
What it measured
Main measures
Brain carnosine change
Baseline vs. eight weeks
Other measures (4)
Health-related quality of life with SF36 Questionnaire change
Baseline vs. eight weeks
Quality of life (reported by participants)Change in neuromuscular performance for autonomic dysfunction (Ewing)
Baseline vs. eight weeks
Change in multidimensional fatigue
Baseline vs. eight weeks
FatigueChange in blood clinical chemistry panel
Baseline vs. eight weeks
Who could take part
MS (type not specified) · 18 to 65
Show the full criteria
Inclusion criteria
* Age ≥ 18 years * Body mass index 19 - 30 kg/m2 * Free of major chronic diseases or acute disorders besides MS * Fulfilled 2017 McDonald Criteria for the diagnosis of MS
Exclusion criteria
* Pregnancy * Psychiatric comorbidity * Use of dietary supplements within 4 weeks before study commences * Unwillingness to return for follow-up analysis * Abnormal values for lab clinical chemistry (> 2 SD) * Immunotherapy for the past 6 months * Treated with systemic corticosteroids during the 30 days before study commences
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Low levels of tissue carnosine and mitochondrial dysfunction appears to accompany multiple sclerosis (MS), with oral carnosine might be applicable to tackle impaired bioenergetics and oxidative stress in MS, and perhaps win back neuromuscular function. However, several formulations of carnosine have shown limited applicability due to restraints in brain delivery or tissue performance. No human studies so far evaluated the impact of innovative carnosine formulation (Karnozin EXTRA) in MS. Here, we will evaluate the impact of supplemental carnosine on neuromuscular performance, brain biomarkers of carnosine metabolism, and health-related quality of life in a case series of patients with MS.
Papers
Background
Keytsman C, Blancquaert L, Wens I, Missine M, Noten PV, Vandenabeele F, Derave W, Eijnde BO. Muscle carnosine in experimental autoimmune encephalomyelitis and multiple sclerosis. Mult Scler Relat Disord. 2018 Apr;21:24-29. doi: 10.1016/j.msard.2018.02.013. Epub 2018 Feb 11.Background
Sariev AK, Abaimov DA, Tankevich MV, Pantyukhova EY, Prokhorov DI, Fedorova TN, Lopachev AV, Stvolinskii SL, Konovalova EV, Seifulla RD. [Experimental study of the basic pharmacokinetic characteristics of dipeptide carnosine and its efficiency of penetration into brain tissues]. Eksp Klin Farmakol. 2015;78(3):30-5. Russian.
Loading reviews and guidelines…
History
Started
Jun 2019
Main results due
Nov 2019
Finished
Dec 2019